

Segment	Major Product	Existing	Expansion	Total	Dec Qtr	Mar Qtr	June Qtr	Sept Qtr	Growth % with March 21	Company Comments
		MT/Annum			Amt (In Lakhs)					
Anti-hypertensive	Atenolol	300	120	420	1,418.22	1,153.85	491.38	1,401.61	21%	Received approval from US FDA,European FDA and Chinese SFDA. Poised to gain a major market share of the US market in next two years
Macrolides	Azithromycin	30	60	90	3,084.68	3,428.68	732.41	1,253.08	-63%	During the pandemic, COVID-19, we are manufacturing Azithromycin, an anti-biotic used for its treatment. Addition of new products is to sustain the market competition
Steriles Carbapenems	Meropenem	6	54	60	739.80	1,930.04	1,769.43	3,042.93	58%	1st Company to receive DGCAI approval for launch of Biapenem in India and commercialise.1st Company to launch Biapenem in Russia..One of the major players in Sterile Carbapenems
Steriles Cephalosporin	Ceftriaxone	96	84	180	702.83	832.15	739.07	239.92	-71%	Developing the entire range of carbapenems
Neuromodulator	Pregabalin	30	30	60	317.03	326.72	301.09	431.09	32%	Pregabalin DMF filed with US FDA
Anti-thrombosis	Ticagrelor		6	6	6.79	32.1		92.64	189%	It is used for the prevention of stroke, heart attack and problems with blood supply in the coronary arteries.Got Commercialized in the quarter Q3 2020-21.Ticagrelor DMF will be filed with US FDA by 31st Dec 2021.Launched Ticagrelor in H1 2021-22
Urological	Nitroxoline		33	33	43.02	363.63	510.54	895.57	146%	Filed process patent applications for Nitroxoline in India, EU and China.Registered Nitroxoline in Germany
Gastroenterology					83.69	52.44	34.33	48.48	-8%	
Advance Intermediate					105.84	11.14	50.00	13.80	24%	
Anti-infective/Anti Acne					6.79					
Other API Product sales				0	373.48	19.77	70.20	46.85	137%	
Anti Diabetics	Canagliflozi/Dapagliflozin		6	6						Build Anti-diabetic and Anti-thrombosis product portfolio
	Other Drugs	6	63	69						
Formulations					4,508.09	5,785.05	2,893.68	5,590.67	-3%	Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs. Catering 100% export markets of both Regulated and Non-Regulated markets The contraction in margins is a result of increase in API prices, packing material costs and freight costs.
Total		468	456	924	11,390.26	13,935.57	7,592.13	13,056.64		

EBIDTA	
EBIDTA %	

2535.46	2432.33	1221.85	2659.48	9%	
22.3%	17.5%	16.1%	20.4%	17%	